Palonosetron for the treatment of chemotherapy induced emeses
AssigneeHelsinn Healthcare SA
InventorsAlberto Macciocchi, Sergio Cantoreggi, Enrico Braglia, Riccardo Braglia, Simone Macciocchi, Giulio Macciocchi
Life of this patent
Estimating the term…
Abstract
Methods and compositions for reducing chemotherapy and radiotherapy induced emises with 5-HT3 receptor antagonists are disclosed, especially with palonosetron.
Claims27
1) A method of treating chemotherapy or radiotherapy-induced acute and delayed emesis comprising administering to an animal a treatment-effective amount of palonosetron.
15) A method of treating chemotherapy or radiotherapy-induced emesis in an animal comprising administering a dose of 0.25 mg of palonosetron to the animal.
26) A method of preventing chemotherapy or radiotherapy induced emesis comprising:
- a) in a first chemotherapeutic or radiotherapy session:
- i) administering to a human a first amount of palonosetron;
- and
- ii) administering to said human an emesis inducing amount of a chemotherapeutic agent or radiotherapy;
- b) assessing the effectiveness of the palonosetron;
- and
- c) in a subsequent chemotherapeutic or radiotherapy session, if said human is at least partly non-responsive to said palonosetron in said first chemotherapeutic session, administering to said animal a therapeutically effective amount of a second anti-emetic compound;
- and
- d) wherein the subsequent chemotherapeutic session is performed without an intervening chemotherapeutic session in which a second amount of palonosetron higher than the first amount is administered.
27) A method of preventing chemotherapy or radiotherapy induced emesis comprising, in one chemotherapeutic or radiotherapy session:
- a) administering to a human a first dose of palonosetron;
- and
- b) administering to said animal an emesis inducing amount of a chemotherapeutic agent or radiotherapy;
- c) assessing the effectiveness of the palonosetron;
- and
- d) if said human is at least partly non-responsive to said first dose of palonosetron, not administering a second dose of palonosetron for at least 24 hours after step (b).
Dependencies are inferred from the claim text.